clinicians preference when semaglutide is not suitable For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg What Is the Dark Side

The Rx gene from potato controls separate virus resistance and cell death responses

Walking 30 minutes daily is a simple, sustainable baseline

When restriction has already been part of the story, adding a medication that suppresses appetite is not a neutral intervention. Gastrointestinal Conditions That Require Caution Because GLP-1 medications slow gastric emptying and affect gut motility, certain GI conditions need special caution

Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia

Is GLOW the same as KLOW

Ozempic may contribute to an increased risk for thyroid c-cell tumors, acute pancreatitis, gallbladder disease, hypoglyceia, acute kidney injury, severe GI side effects, and an increased risk for worsening of diabetic retinopathy in people with type 2 diabetes